Exacerbation Reduction in Patients with Asthma Following Escalation to FF/UMEC/VI from ICS/LABA: Retrospective Cohort Study
In patients who remain uncontrolled despite ICS/LABA treatment, escalating to FF/UMEC/VI is associated with reductions in asthma exacerbations, asthma-related hospitalizations, OCS use, SABA use, and asthma-related medical costs.
Authors
- Alan P. Baptist (ORCID: https://orcid.org/0000-0001-8284-0027)
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Rosirene Paczkowski (ORCID: https://orcid.org/0009-0001-7151-4311)
- Alison Moore
- Robert C. Schell (ORCID: https://orcid.org/0000-0002-1252-0826)
- Stephen G. Noorduyn (ORCID: https://orcid.org/0000-0002-5936-5579)
- Sergio Forero-Schwanhaeuser
- Guillaume Germain
- J. Klimek
Institutions
- World Health Organization - Pakistan (PK)
- Henry Ford Health System (US)
- Menlo School (US)
- GlaxoSmithKline (Canada) (CA)
- Group for Research in Decision Analysis (CA)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Durham VA Medical Center (US)
- Impact (CA)
- Analysis Group (United States) (US)
- McMaster University (CA)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1007/s41030-025-00327-w
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00